Advancing cross-linking mass spectrometry to elucidate cellular networks

Value of the Information & Strength of the Argument

The presentation provides substantial value by showcasing novel XL-MS technologies and their applications to clinically relevant samples. The argumentation is solid, grounded in experimental data and published studies. The speaker clearly explains the technical challenges and how their innovations address them, such as the development of MS-cleavable cross-linkers to simplify peptide identification. The use of TMT labeling for quantitative analysis is well-justified, and the presentation of stage-dependent interaction changes in gastric cancer is compelling. The argument that XL-MS provides information beyond protein abundance is supported by examples where interaction changes occur without corresponding expression changes. The inclusion of unpublished data from the CPTAC project adds novelty but also introduces some uncertainty. Overall, the value is high, and the argumentation is coherent and evidence-based.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with detailed methodological descriptions and references to published work. The speaker cites her own publications and collaborations, such as the Nature Cancer paper on AML. However, specific citations are not explicitly listed in the video, and the description lacks direct links to sources. The title accurately reflects the content, focusing on advancements in XL-MS and their application to cellular networks. The presentation is well-structured and technically sound, though some data are unpublished and thus not yet peer-reviewed. The adequacy between title and content is good, with no significant mismatch.

The title accurately reflects the content, focusing on advancements in cross-linking mass spectrometry and its application to cellular networks.

8/10

The presentation is based on peer-reviewed research and includes detailed methodological descriptions, but it is a webinar with limited external verification and some unpublished data.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the importance of protein-protein interactions and the need for systematic analysis.
• 06:00Overview of cross-linking mass spectrometry (XL-MS) and its advantages over affinity-based methods.
• 10:00Development of DSSO and DSPSO MS-cleavable cross-linkers and their mechanism.
• 15:00Application of DSPSO to HEK293 cells to map protein interaction networks.
• 20:00Application to clinical samples: breast cancer PDX models and gastric cancer tissues.
• 25:00TMT-based quantitative XL-MS workflow for gastric cancer samples.
• 30:00Identification of stage-dependent interaction rewiring and correlation with protein abundance.
• 35:00Examples of novel inter-protein interactions and their structural implications.
• 40:00Collaboration on membrane protein complexes and AML therapeutic targeting.
• 45:00Development of cysteine-reactive and multi-linker cross-linkers to expand coverage.

• Nature Cancer publication on AML integrin conformation — Mentioned as a collaborative work with Professor Aron Wita's lab at UCSF, published in Nature Cancer.

• Nature Cancer publication on AML integrin conformation — Mentioned as a collaborative work with Professor Aron Wita's lab at UCSF, published in Nature Cancer.